Echo IQ (EIQ) H2 2024 earnings summary

Executive summary

• Achieved significant milestones in clinical validation, commercialisation, and regulatory progress, including successful clinical studies and integration partnerships for AI-powered cardiac diagnostics solutions.

• FDA clearance application for aortic stenosis solution submitted in May 2024, with a decision expected imminently; heart failure solution clinical studies underway.

• Raised $7.1 million post-year-end to fund US commercialisation and completed strategic integration partnerships.

Financial highlights

• Reported net loss of $5,409,146 for FY24, an improvement from $7,855,622 loss in FY23.

• Operating revenue was $44,500, down from $107,332 in the prior year.

• Net assets decreased to $6,767,992 from $7,382,771 year-over-year.

• Cash outflow from operations was $3,924,196, with net cash inflow from financing activities of $2,764,999.

Outlook and guidance

• Focused on accelerating commercialisation post-FDA clearance, expanding partnerships, and securing reimbursement codes in the US.

• Ongoing investment in product innovation and clinical studies to support regulatory and market expansion.